Dr. Robert S. Alter, MD

Dr. Alter practices at Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health.

Dr. Alter's NPI, 1306805460, was assigned on March 18, 2006. Dr. Alter graduated from Chicago Medical School/Rosalind Franklin University of Medicine Science in 1988. Dr. Alter holds New Jersey license 25MA06465900.

Dr. Alter's primary practice is Hackensack University Medical Center, at 30 Prospect Ave, Hackensack, NJ 07601 in Bergen County. The practice phone is (551) 996-2000.

Dr. Alter's primary practice is Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health. Dr. Alter is also affiliated with Englewood Hospital. The medical group on file is Regional Cancer Care Associates. Dmand AI also links Dr. Alter to 3 more hospitals, 2 group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alter practices, 8 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Alter's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Alter is licensed in New Jersey.

CMS data shows 13,974 Medicare services from Dr. Alter across 14 procedure codes in 2024, for 800 Medicare patients. Medicare paid $497,609 for them.

CMS counts 800 Medicare patients who saw Dr. Alter in 2024. The largest group is 65 to 74, with 318 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alter's median patient age at 71, with 28% women.

In 2024, Dr. Alter wrote 2,174 Medicare Part D claims for 329 patients. 67% of them were for generic drugs. CMS names the drug for 1,930 of them, across 28 drugs with 11 or more claims each, at $8,589,513 in total drug cost. In 2023, CMS named 1,694 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Alter for performance year 2024, reported individually. Dr. Alter accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Alter, published from 2016 to 2024. 2018 was the busiest year, with 2. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Dr. Alter has published most often in J Immunother Cancer. Dr. Alter's most frequent co-authors are Michael B. Atkins, MD, Elizabeth R. Plimack, MD and David Francis McDermott, MD.

Dmand AI links Dr. Alter to 11 clinical trials, 4 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Urinary Bladder Neoplasms, Urinary Bladder Diseases and Carcinoma, Renal Cell. National Cancer Institute (NCI) sponsors the most, 6. Open Payments lists research payments to Dr. Alter that name 1 trial.

CMS Open Payments shows 2,057 general payments to Dr. Alter from 63 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 56% of the total. Exelixis Inc. paid the most, $107,388. It also lists 3 research payments totaling $1,753 from 2016 to 2023, naming 1 clinical trial.

Dr. Alter graduated from Chicago Medical School/Rosalind Franklin University of Medicine Science in 1988.